Table 3.
Hazard of mortality
| Hazard of mortality (0–12 months) during infancy |
Hazard of mortality (12–72 months) for children who survived to 12 months of age |
||||||||
|---|---|---|---|---|---|---|---|---|---|
| Without baseline CD4% |
With baseline CD4% |
||||||||
| HR* | 95% CI | p-value | HR** | 95% CI | p-value | HR*** | 95% CI | p-value | |
| Male sex | 0.54 | [0.32,0.92] | 0.023 | 0.30 | [0.08,1.12] | 0.073 | 0.85 | [0.41,1.75] | 0.660 |
| Residence outside of Panama City | 1.72 | [1.01,2.94] | 0.046 | 2.75 | [0.73,10.39] | 0.136 | 0.84 | [0.41,1.74] | 0.641 |
| PMCT | 0.75 | [0.34,1.69] | 0.491 | 0.30 | [0.03,2.76] | 0.290 | 2.45 | [0.30,20.12] | 0.405 |
| ARV Exposure | |||||||||
| ART-naïve | REF | REF | REF | REF | REF | REF | REF | REF | REF |
| Mono/Dual | 0.44 | [0.16,1.26] | 0.127 | 1.56 | [0.30,8.23] | 0.600 | 1.82 | [0.83,3.96] | 0.132 |
| HAART (any) | 0.32 | [0.12,0.83] | 0.019 | 1.28 | [0.24,6.94] | 0.776 | |||
| HAART (LPVr-based) | 0.07 | [0.01,0.33] | 0.001 | ||||||
| HAART (non-LPVr) | 0.30 | [0.06,1.40] | 0.124 | ||||||
| Baseline CD4% < 15% | 6.62 | [1.74,25.21] | 0.006 | ||||||
*
n = 191 children enrolled from 0–12 months of age (excludes 11 children with missing data for ≥ 1 variable in the regression model)
**
n = 104 children enrolled from 0–12 months of age with baseline CD4% available
***
n = 252 children who survived to 12 months of age (excludes 20 children with missing data for ≥ 1 variable in the regression model)
ARV= Antiretroviral Therapy, LPV/r= Lopinavir/ritonavir, HAART= Highly active antiretroviral therapy